ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / SABS / insiders
AGEN (29) SCTX (43) EIKN (43) ALEC (33) ⌘ Pro Terminal →

SAB Biotherapeutics Inc. (SABS) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$3.35 +3.72% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.37

SAB Biotherapeutics Inc. (SABS) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $304.8M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SABS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SABS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, SAB Biotherapeutics Inc. (NASDAQ: SABS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $3.35 (+3.72% 1D, market cap $304.8M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 4/20. Across 1015 tracked Health Care issuers, SABS ranks #508 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SABS compare to AGEN and SCTX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SABS carries a Roarable D- (38/100 RQD), trailing P/E of 22.1x, gross margin of —, and ROIC of -27.4%. By comparison, AGEN (Agenus Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $308.9M) and SCTX (Scribe Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC —, cap $291.9M). Among the 5-stock peer group, SABS leads on earnings multiple (22.1x) while SABS leads on capital efficiency (-27.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SABS?
▼

Per SABS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001833214), SAB Biotherapeutics Inc. generated $137.1M in revenue (+10265.1% YoY), $13.3M in net income, and -$45.7M in free cash flow against $172.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $3.37 (+0.48%)🧬 Dilution Drag (+2.20% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510038
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (5)Whales (9)SEC (13)Macro (7)CEO (4)
Each axis scored 0–20
12M PRICE TARGET CONE-9% Base Target
$5 Bull$3 Base$2 Bear
📬 FREE SABS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SABS)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (38/100 Composite)
🔍 WHY SABS SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (34% of score)

Altman Z-Score 7.07 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Whale & Options Positioning+9/20 pts (24% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.20% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
30
Grade E$2.68+7.5% Next Q
Q2 (-2Q)
33
Grade E$2.88+6.6% Next Q
Q3 (-1Q)
35
Grade E$3.07+9.1% Next Q
Current
38
Grade D-$3.35-7.8% Hist 90D α
Trajectory: E (30) → D- (38)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SABS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SABS currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.24) and Max Pain ($3.52) forces dealer call-delta covering toward $5.41.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.20% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SABS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SABS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 38%NO 62%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

SABS Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (SABS)

No recent open-market Form 4 cluster sales or emergency dumps flagged on SABS. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SABS)

  • ✓Walkthrough of SABS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
SABS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -9.21%⚡ TESTING RESISTANCE
2026-11-03O $3.23H $3.35L $3.23C $3.35VOL 741.1K
RES: $3.34SUP: $2.34SMA50: $3.24SMA200: $3.67
$4.74$4.12$3.49$2.87$2.25RES $3.34SUP $2.34$3.352026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SABS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SABS Butterfly Map → + Track SABS →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
15.8%/yr Implied 5Y Growth

vs. +10265.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SABS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SABS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SABS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SABS)

Health Care Rank #508 of 1015 ⚔️ AGEN vs SABS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SABS vs. AGEN, SCTX, EIKN, ALEC)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, SAB Biotherapeutics Inc. (SABS) ranks #508 by composite RQD confidence (38/100, grade D-) and #515 by equity capitalization ($304.8M). Within this direct 5-issuer industry benchmark cohort, SABS leads on earnings valuation at 22.1x trailing P/E, while SABS leads on capital efficiency and profitability with -27.4% ROIC and — gross margin. SCTX currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with SABS at 38/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SABS ACTIVE
SAB Biotherapeutics Inc.
D- 38/100 22.1x — -27.4% +3.72% $304.8M Benchmark Subject
AGEN
Agenus Inc.
E 29/100 — 96.0% -35.0% -3.53% $308.9M /agen-vs-sabs →
SCTX
Scribe Therapeutics Inc.
D- 43/100 — — — -11.58% $291.9M /sctx-vs-sabs →
EIKN
Eikon Therapeutics Inc.
D- 43/100 — — — -0.75% $287.6M /eikn-vs-sabs →
ALEC
Alector Inc.
E 33/100 — — -35.0% -1.34% $327.6M /alec-vs-sabs →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001833214 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), SAB Biotherapeutics Inc. (SABS) reported GAAP revenue of $137.1M (+10265.1% vs. FY2024 revenue of $1.3M , and +6021.9% cumulative change since FY2023) , GAAP net income of $13.3M, operating cash flow of -$44.8M, and free cash flow of -$45.7M (-32.0% YoY). On the balance sheet, SABS closed FY2025 with $172.8M in total assets against $0 in total debt (Altman Z-Score: 7.07, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $137.1M $13.3M -$44.8M -$45.7M $172.8M —
FY2024 (FY) 2024-12-31 $1.3M -$34.1M -$34.3M -$34.6M $44.2M —
FY2023 (FY) 2023-12-31 $2.2M -$42.2M -$25.1M -$25.1M — —

3. SABS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SABS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, SAB Biotherapeutics Inc. (NASDAQ: SABS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $3.35 (+3.72% 1D, market cap $304.8M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 4/20. Across 1015 tracked Health Care issuers, SABS ranks #508 in composite RQD confidence.

How does SABS compare to AGEN and SCTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SABS carries a Roarable D- (38/100 RQD), trailing P/E of 22.1x, gross margin of —, and ROIC of -27.4%. By comparison, AGEN (Agenus Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $308.9M) and SCTX (Scribe Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC —, cap $291.9M). Among the 5-stock peer group, SABS leads on earnings multiple (22.1x) while SABS leads on capital efficiency (-27.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SABS?

Per SABS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001833214), SAB Biotherapeutics Inc. generated $137.1M in revenue (+10265.1% YoY), $13.3M in net income, and -$45.7M in free cash flow against $172.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SABS trading relative to its 50-day, 200-day, and 52-week technical levels?

SABS last traded at $3.35 (+3.72% on volume of 741,056 shares), positioning the stock +3.40% above its 50-day simple moving average ($3.24) and -8.72% below its 200-day simple moving average ($3.67). Across its 52-week range of $2.44 to $5.15, SABS sits at the 33.6% percentile with a 14-day RSI of 59.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($2.93 to $3.77).

Direct Sub-Reports: SABS RQD Cockpit SABS 12M Forecast SABS Earnings & Move SABS Dividends & DRIP SABS Insiders & 13F SABS Whale Options SABS Profit Sankey SABS News & Why
ROARABLE RATING BRIEF • RQD 38/100 (D-) ✓ SEC XBRL & RQD VERIFIED

SABS — SAB Biotherapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

SAB Biotherapeutics Inc. (SABS) earns a live Roarable RQD composite score of 38/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $3.35 (+3.72% 1D, market capitalization $304.8M).

  • Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -27.4%, gross margin of —, operating margin of —, and free cash flow yield of -15.55%.
  • Whale 13F & Options Flow (9/20) + Insider Conviction (4/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of 7.07, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

SAB Biotherapeutics Inc. (SABS) is a NASDAQ-listed issuer in the Health Care sector, classified under Biotechnology: Biological Products (No Diagnostic Substances). It has a market capitalization of $0.3B. Per the recent news wire, the company's pipeline activity includes SAB-142, which received FDA Fast Track Designation in Type 1 Diabetes.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), SAB Biotherapeutics Inc. (SABS) reported $137.1M in annual revenue (up from $1.3M in FY2024, +10265.1% YoY) and $13.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.2M revenue, -$42.2M net income) through FY2025, SABS scaled operating cash flow to -$44.8M and free cash flow to -$45.7M, backed by $172.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 38/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -15.55% and institutional whale pillar of 9/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $2.44 – $5.15 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh 22.1x trailing P/E against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The only sector-level context is that SABS sits in Health Care / Biological Products; any second-order ripple analysis would require data not provided here.

  • Key Question #1: Can SABS sustain or expand its — operating margin and -27.4% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $137.1M and free cash flow of -$45.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is SABS's 20.6x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SABS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for SAB Biotherapeutics Inc. (SABS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SABS Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SABS Bull vs. Bear Conversation Board — What's Your Call at $3.35?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SABS 🐻 33% BEARISH CONVICTION
1. Pick Your Side on SABS:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $3.99 (+19.1%)
📌 Pinned Debate

Per the Roarable RQD rating, the forensic balance sheet scores 13/20 with an Altman Z of 7.07, indicating relative solvency resilience

Don't sleep on SABS's setup in Health Care. Per the Roarable RQD rating, the forensic balance sheet scores 13/20 with an Altman Z of 7.07, indicating relative solvency resilience despite weak cash flows.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (38/100) backs up the fundamental quality.

RetailWhale_TX 🐂 BULL

Both sides have a point here — SABS's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $2.85 (-14.9%)
Spot @ $3.35

Per the Roarable RQD rating, ROIC of -27.4% and FCF yield of -15.55% show the business consuming cash, so the 22.1 P/E is not backed by

Here is the bear case nobody on the bull side wants to address on SABS: Per the Roarable RQD rating, ROIC of -27.4% and FCF yield of -15.55% show the business consuming cash, so the 22.1 P/E is not backed by operating returns.. At 22.1x trailing P/E, even a small guidance miss in Biotechnology: Biological Products (No Diagnostic Substances) triggers a 12-15% air pocket.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%